Net Loss for the year was (6.05
M).
The performance of Alzamend Neuro in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Alzamend Neuro's
stock prices. When investing in Alzamend Neuro, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Alzamend Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Alzamend Neuro carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
Watch out for price decline
Please consider monitoring Alzamend Neuro on a daily basis if you are holding a position in it. Alzamend Neuro is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Alzamend Neuro stock to be traded above the $1 level to remain listed. If Alzamend Neuro stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Alzamend Neuro's Liquidity
Alzamend Neuro
financial leverage refers to using borrowed capital as a funding source to finance Alzamend Neuro ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Alzamend Neuro financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Alzamend Neuro's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Alzamend Neuro's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Alzamend Neuro's total debt and its cash.
Alzamend Neuro Gross Profit
Alzamend Neuro Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Alzamend Neuro previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Alzamend Neuro Gross Profit growth over the last 10 years. Please check Alzamend Neuro's
gross profit and other
fundamental indicators for more details.
Breaking down Alzamend Neuro Indicators
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Alzamend suggests not a very effective usage of assets in November.
Alzamend Neuro implied volatility may change after the rise
The variance is down to 55.74 as of today. Alzamend Neuro is displaying above-average volatility over the selected time horizon. Investors should scrutinize Alzamend Neuro independently to ensure intended market timing strategies are aligned with expectations about Alzamend Neuro volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Alzamend Neuro's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Alzamend Neuro's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Alzamend Neuro Implied Volatility
Alzamend Neuro's implied volatility exposes the market's sentiment of Alzamend Neuro stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Alzamend Neuro's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Alzamend Neuro stock will not fluctuate a lot when Alzamend Neuro's options are near their expiration.
The Current Takeaway on Alzamend Neuro Investment
Whereas other companies in the biotechnology industry are either recovering or due for a correction, Alzamend Neuro may not be performing as strong as the other in terms of long-term growth potentials. To summarize, as of the 23rd of November 2021, we believe that Alzamend Neuro is currently
undervalued with
above average probability of distress in the next two years. However, our present 90 days 'Buy-vs-Sell' recommendation on the company is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Alzamend Neuro. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
